The proxy fight outcome is binary and will be decided at the June 9 meeting. Management's strong operating results and buyback program support the incumbent board, but DOMA's activist campaign introduces uncertainty around capital allocation and strategic direction. Watch for proxy advisory firm recommendations (ISS/Glass Lewis) and institutional investor voting patterns in the coming days.
Price Chart
Executive Summary
Pacira BioSciences filed additional definitive proxy soliciting materials (DEFA14A) urging stockholders to vote FOR management's director nominees on the BLUE proxy card at the June 9, 2026 annual meeting, directly countering activist DOMA Perpetual Capital Management's dissident slate. The filing highlights record 2025 financial results ($726.4M revenue, 79.4% GAAP gross margins), strong Q1 2026 momentum across all commercial products, a $300M buyback program with $200M returned, and a favorable EXPAREL patent settlement securing exclusivity through 2030. Management characterizes DOMA's campaign as seeking to replace the board with unqualified candidates, cut R&D, and pursue a fire sale.
Key Facts
- Annual meeting scheduled June 9, 2026; record date April 22, 2026
- Activist DOMA Perpetual Capital Management nominating three director candidates
- Pacira achieved record 2025 total revenue of $726.4M and GAAP gross margins of 79.4%
- Q1 2026: EXPAREL revenue $143.3M (+5% YoY), ZILRETTA $26.8M (+15%), iovera $6.2M (+21%)
- $300M share repurchase authorized April 2025; $200M returned to stockholders through March 31, 2026
- Favorable volume-limited EXPAREL patent settlement secures exclusivity through 2030
- Board would be 89% independent with ~4.6 year average tenure after annual meeting
- Goldman Sachs acting as financial advisor; Perkins Coie as legal counsel
Financial Impact
Record 2025 revenue of $726.4M; Q1 2026 EXPAREL revenue $143.3M (+5% YoY); $200M returned via buyback since April 2025
Risk Factors
- Activist DOMA could win board seats, leading to strategic shift, cost cuts, or sale process
- Proxy contest may distract management from commercial execution and pipeline advancement
- Patent settlement terms (volume-limited) could constrain EXPAREL growth trajectory
- Heavy reliance on EXPAREL revenue concentration remains a key business risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-036972 |
| Document: 0001628280-26-036972-index-headers.html | 0001628280-26-036972 |
| Document: 0001628280-26-036972-index.html | 0001628280-26-036972 |
| Document: 0001628280-26-036972.txt | 0001628280-26-036972 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access